News & Media
Learn more about the latest happenings at Otsuka. Select to see US news or read our press releases. You can also stay up to date with our global news in the link below.
Otsuka Pharmaceutical Development & Commercialization, Inc. and Verily, an Alphabet precision health company announced their expanded work together on innovative approaches to clinical trials studying treatments for adults with Major Depressive Disorder (MDD).
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce the U.S. Food and Drug Administration has determined that the supplemental New Drug Application for brexpiprazole for use in the treatment of agitation associated with Alzheimer’s dementia is sufficiently complete to permit a substantive review.
Otsuka Pharmaceutical Development & Commercialization, Inc. and Sunovion Pharmaceuticals Inc. announced that the first patient has been enrolled in a Phase 2/3 clinical study to evaluate ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, as an adjunctive therapy in the treatment of adults living with major depressive disorder.
Otsuka America Pharmaceutical, Inc., and Lundbeck US presented positive efficacy and safety data from multiple Phase 3 studies of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia at the Clinical Trials for Alzheimer’s Disease (CTAD) Congress in San Francisco, CA.